March 31, 2022 | Cogstate, Decentralized trials, Impetus Digital, Natalie Yeadon, Pam Ventola, brain health, central rating, central scoring, clinical insights, clinical trials, cognitive testing, digital assessments, rare disease
Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can help advance the development of new medicines and enable earlier clinical insights. She also discusses cognitive testing as part of decentralized trials, the role of central rating and central scoring, the development of indication-specific COAs for rare disease trials, and much more.
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
Based on 13 years of experience in virtualizing life science meetings and events
Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches…
Cassie Solomon, CEO of The New Group Consulting, dives into the future of innovation, digital technologies, and systems thinking in healthcare. Among many other things, we discuss how organizations can prepare…
A customer story
Laura Towart, Founder & CEO of My Personal Therapeutics, discusses her company’s approach to precision medicine, the barriers patients with cancer face when trying to access personalized treatments, and how…
Kim Shah, CEO of KnowYourMeds, explores digital health, AI, telemedicine, health literacy, and how to ensure a safe return to work amidst the ongoing COVID-19 pandemic. We also dive into…
Dr. Oscar Segurado, Chief Medical Officer at ASC Therapeutics, dives into advanced gene therapies, gene editing, and personalized medicine. We also explore the many different hats he wears as CMO, consultant,…
John Leombruno, CEO of OkRx, shares how his company is working to improve PSP strategy and operations in Canada. He also discusses the impact of COVID-19 on PSPs, digital transformation, clinical…
Chad Walsh, CEO of Sciteline, dives into virtual trials, including their benefits, barriers, and impact on patient-centricity. Among other things, we will discuss data privacy concerns, the role of digital…
Owen Muir, MD, CIO at Brooklyn Minds, explores the secondary effects of COVID-19 on mental health conditions, along with techniques such as deep Transcranial Magnetic Stimulation (dTMS), Mentalization-Based Treatment (MBT), and…
